5′RNA Trans-Splicing Repair of COL7A1 Mutant Transcripts in Epidermolysis Bullosa

• Published in: International journal of molecular sciences Vol. 23; no. 3; p. 1732
• Main Authors: Mayr, Elisabeth, Ablinger, Michael, Lettner, Thomas, Murauer, Eva M., Guttmann-Gruber, Christina, Piñón Hofbauer, Josefina, Hainzl, Stefan, Kaiser, Manfred, Klausegger, Alfred, Bauer, Johann W., Koller, Ulrich, Wally, Verena
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 01.02.2022; MDPI
• Subjects: Artificial chromosomes; Collagen; Efficiency; Fibroblasts; Gene expression; Kinases; Mutation; Patients; Proteins; Skin; Stem cells
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms23031732

Mutations within the COL7A1 gene underlie the inherited recessive subtype of the blistering skin disease dystrophic epidermolysis bullosa (RDEB). Although gene replacement approaches for genodermatoses are clinically advanced, their implementation for RDEB is challenging and requires endogenous regulation of transgene expression. Thus, we are using spliceosome-mediated RNA trans-splicing (SMaRT) to repair mutations in COL7A1 at the mRNA level. Here, we demonstrate the capability of a COL7A1-specific RNA trans-splicing molecule (RTM), initially selected using a fluorescence-based screening procedure, to accurately replace COL7A1 exons 1 to 64 in an endogenous setting. Retroviral RTM transduction into patient-derived, immortalized keratinocytes resulted in an increase in wild-type transcript and protein levels, respectively. Furthermore, we revealed accurate deposition of recovered type VII collagen protein within the basement membrane zone of expanded skin equivalents using immunofluorescence staining. In summary, we showed for the first time the potential of endogenous 5′ trans-splicing to correct pathogenic mutations within the COL7A1 gene. Therefore, we consider 5′ RNA trans-splicing a suitable tool to beneficially modulate the RDEB-phenotype, thus targeting an urgent need of this patient population.